With growing momentum for the PSC, 13 new partners join the Carbon
Black Integration Network (CBIN) utilizing the company’s open APIs
SAN DIEGO & WALTHAM, Mass.–(BUSINESS WIRE)–Carbon
Black (NASDAQ:CBLK), a leader in cloud endpoint protection, today
welcomed more than 150 developers to its sold-out Developer Day, kicking
off Carbon Black’s annual three-day user conference, #CBConnect19.
Developer Day features in-depth, technical workshops designed to
accelerate developers’ ability to advance API and integration techniques
and extend Carbon Black’s open cloud platform, the CB
Predictive Security Cloud® (PSC).
“To create the strongest security posture possible in today’s evolving
threat landscape, companies need access to rich and comprehensive
endpoint data,” said Scott Lundgren, Carbon Black’s Chief Technology
Officer. “By offering open APIs for all of our products and making every
layer of the Carbon Black stack natively extensible, our customers can
custom-build their security stack with integrated solutions that quickly
and effectively address new threats and offer better protection against
The PSC allows third-party developers to leverage Carbon Black’s
unfiltered data from the endpoint to the cloud. With native
extensibility, the PSC makes it easy for developers to improve an
organization’s security posture by building extensions including:
Integrations with external systems, such as SIEMs and custom-analysis
pipelines, to streamline reporting and analytics across the tech stack
Scripting of endpoint actions via external triggers, such as alerts,
allowing the automated orchestration of custom actions to be taken on
Endpoint data collection via osquery,
an open source monitoring and collection tool that anyone can extend
Customized threat intelligence to enhance real-time detection of
Carbon Black Launches Open Source Tool For High-Volume Analytics
At this year’s Developer Day, the company announced the release of an
event query router (EQR), a new, open-source data analytics tool that
gives data scientists the ability to execute large-scale queries on
real-time big data streams without writing code or batching
transactions. EQR was initially built by Carbon Black engineers to
address the needs of our Threat Analytics Unit (TAU) for threat research
and our managed detection service, CB ThreatSight, which requires
high-bandwidth, low-latency access to analyze billions of security
events generated by our customers through the PSC. Recognizing the
benefit of being able to quickly consume streams of data at massive
scale for a range of industries and applications, Carbon Black is
delivering EQR as an extensible open-source tool accessible through the Carbon
Black GitHub repository.
“Access to large quantities of data through the cloud is revolutionizing
the way we’re approaching endpoint security — and the ability to not
only analyze that data, but transform it into actionable security
insights for our customers quickly and effectively, is critical to our
success,” said Lundgren. “We’re pleased to be able to share EQR with
other developers in a multitude of industries, who are faced with the
same big data challenges.”
Carbon Black Integration Network
In conjunction with Developer Day at #CBConnect19, Carbon Black
announced that 13 new partners have joined the Carbon
Black Integration Network. CBIN represents vendors, customers and
security technologists that have extended Carbon Black products – often
through custom data ingestion or open APIs documented on GitHub – to
build integrations that benefit an organization’s security posture and
can be leveraged openly by the entire security community. Currently,
more than 120 partners have built more than 140 documented integrations.
New CB Integration Network partners include: Active
Cyber Solutions, Panaseer,
“Managing endpoints is key to maintaining an organization’s threat
posture. Being a part of Carbon Black’s Integration Network and
leveraging their API makes it easy for JupiterOne Customers to collect
endpoint information from Carbon Black, including how the security agent
is configured, and correlate it with the rest of the organization’s
infrastructure. By mapping the vulnerable endpoints and the rest of the
resources a user can access across your infrastructure, JupiterOne with
Carbon Black enables a better understanding of the significance of
threats,” said Erkang Zheng, General Manager at JupiterOne.
“Enterprises are facing a security visibility issue; they are
struggling to keep up with the proliferation of devices across cloud,
mobile and IoT. We believe the integration between Panaseer’s Continuous
Controls Monitoring platform and Carbon Black’s rich datasets, through
its extensive open APIs, provides enterprises with an unparalleled view.
It allows customers to validate Carbon Black has been installed across
all devices and identify any coverage gaps. Through Panaseer’s
remediation campaign tracking they can also monitor the progress and
current status of any required corrective actions,” said Charaka
Goonatilake, Chief Technology Officer at Panaseer.
“The openness of Carbon Black and the quality of the data it provides
allows Pliant.io to automate effective responses with unprecedented
confidence. Pliant’s workflow automation visually abstracts code
from process allowing users to quickly create very sophisticated and
robust workflows across multiple domains or silos responding immediately
to threats uncovered by Carbon Black,” said Vess Bakalov, Chief
Executive Officer at Pliant.io.
About Carbon Black
Carbon Black (NASDAQ: CBLK) is a leader in cloud endpoint protection
dedicated to keeping the world safe from cyberattacks. The CB Predictive
Security Cloud® (PSC) consolidates endpoint protection and IT operations
into an extensible cloud platform that prevents advanced threats,
provides actionable insight and enables businesses of all sizes to
simplify operations. By analyzing billions of security events per day
across the globe, Carbon Black has key insights into attackers’
behaviors, enabling customers to detect, respond to and stop emerging
More than 5,300 global customers, including 35 of the Fortune 100, trust
Carbon Black to protect their organizations from cyberattacks. The
company’s partner ecosystem features more than 500 MSSPs, VARs,
distributors and technology integrations, as well as many of the world’s
leading IR firms, who use Carbon Black’s technology in more than 500
breach investigations per year.
Carbon Black and the CB Predictive Security Cloud are registered
trademarks or trademarks of Carbon Black, Inc. in the United States
and/or other jurisdictions.
Valens expands Exclusive Licence Agreement to Bring Leading Cannabis-Infusion Technology to New International Markets
Valens GroWorks Corp. (TSXV: VGW) (OTCQX: VGWCF) (the “Company” or “Valens“), a cannabinoid-based product company with industry leading extraction, next generation cannabinoid delivery formats and an ISO 17025 accredited analytical lab, is pleased to announce that it has entered an amended manufacturing and sales licence agreement with SōRSE Technology Corporation (“SōRSE“) which grants Valens an exclusive licence for Canada, Europe, Australia and Mexico to use the proprietary SōRSE emulsion technology (“the Technology“) to produce, market, package, sell and distribute cannabis-infused products (the “Agreement“).
“This Agreement shows Valens’ commitment to invest and broaden its IP portfolio and enable its customers to bring differentiated, next generation products to market,” said Jeff Fallows, President of Valens. “As we move into “Cannabis 2.0” in Canada, we believe the products that offer consistent, high quality and predictable user experiences, like those we are able to create with SōRSE, will capture the lion’s share of attention and be the hallmark for brand development in a strict regulatory environment. With this expanded agreement in place, we have extended this opportunity for our existing customers to key international markets and at the same time established a platform for international consumer brands to add high quality, cannabis infused products to their portfolios.”
The SōRSE Emulsion Technology
The SōRSE emulsion technology transforms cannabis oil into water-soluble forms for use in beverages, edibles, topicals and other consumer products without the burden of cannabis taste, colour or smell. The Technology allows these cannabis infused products to maintain potency when heated, chilled or frozen and provides a number of other key advantages as well, including: (1) a faster observed onset time compared to other infused beverages and edibles, (2) a significant reduction of offset time, (3) an ability to use lower doses of cannabinoids due to the enhanced bioavailability provided by the Technology, and (4) increased consistency and stability with some product formulations achieving more than one-year shelf stability with no evidence of separation.
“We are proud to expand our partnership with Valens and leverage their near-term access to various global markets,” says Howard Lee, CEO of SōRSE. “Over the last year, our team of more than 40 plus professionals has continued to actively focus on creating and developing innovative, desirable products and formats of consumption for cannabis consumers. As emulsion technology becomes more popular through new delivery methods such as ingestion, transdermal, topical and more, it is imperative that quality and safety in consumption leads all innovation in this sector. This is a shared value and mandate that our teams at SōRSE and Valens both prioritize. We look forward to continuing this working relationship with Valens and introducing our award-winning emulsion technology to the global markets.”
The Agreement grants Valens an exclusive licence to use the Technology in Canada, Europe, Australia and Mexico (except in respect of medical applications requiring clinical trials) during the initial 5-year term, subject to certain performance milestones. This increases the addressable market from 37 million in the current Canada only agreement to 700 million people in the new Agreement, an increase of almost 20x. Furthermore, the Agreement provides a framework for Valens to obtain rights to establish non-exclusive agreements to sell cannabis-infused products using the Technology in the U.S. market and other markets, globally.
Bolstering “Cannabis 2.0” Platform
With the expanded exclusivity, Valens and its white label clients are positioned to not only succeed in the Canadian market, but also in the rapidly emerging legal cannabis and hemp-derived CBD markets in Europe, Australia, Mexico and beyond. The Agreement adds to the Company’s leading white label product offerings across numerous “Cannabis 2.0” categories such as beverages, edibles, transdermal products and more, enabling Valens to better serve its current and future partners.
“We have seen incredible interest from our current and potential clients regarding the SōRSE emulsion technology and we are thrilled to finalize the expanded licence agreement with SōRSE,” said Tyler Robson, CEO of Valens. “We expect the expanded exclusive territory will provide our clients with improved visibility and greater opportunity as they look to build global businesses around cannabis-infused products over the long term.
This is an exciting time in the evolution of ingestible cannabis products such as beverages and edibles. Historically, ingestible products have been lacking the necessary technology to provide a consistent, predictable experience, ultimately giving little reason to consume in this manner. At Valens, we expect that properly formulated, extract-based cannabis products, and infused beverages in particular, could disrupt many established beverage categories such as soft drinks, sports drinks, value-added water and alcohol, the latter of which has a monthly spend per capita that is roughly 16 times higher compared to legal cannabis spend in Canada. We believe the ability to plan an occasion and predict the outcome of use will be a game changer in the market and be the catalyst to bring about the full market potential of cannabis infused beverages and edibles, globally.”
Future White Label Services
The Agreement furthers the existing relationship between Valens and SōRSE and enables Valens to produce and sell SōRSE’s portfolio of branded products in Canada and the other exclusive markets at the option of the Company. These branded products include Happy Apple, a cannabis-infused sparkling cider and Major, a cannabis-infused fruit drink, both recognized as top selling cannabis beverages in the State of Washington, Pearl20, a cannabis-infused food and beverage mixer, and the Utopia line of cannabis-infused sparkling water, among others.
The consideration at closing for the exclusivity in the expanded geography was US$10 million, comprised of US$6 million in cash and US$4 million to be issued in common shares of the Company (the “Common Shares“). The Agreement carries an initial 5-year exclusive term with a 2-year renewal of the exclusivity, subject to certain performance milestones related to operational and financial achievements (the “Milestones“). As part of the Agreement, Valens will transfer to SōRSE royalty payments calculated as a percentage of sales (the “Royalty Payments“) and the Royalty Payments will be subject to an annual minimum of $2 million over the 5-year term. The Agreement also provides for a continuation of the Agreement on a non-exclusive basis after the 2-year renewal, subject to annual minimum royalty payments.
All Common Shares pursuant to the Agreement were issued at an indicative price of CDN$3.0471, being the volume-weighted average price of the Common Shares on the TSX Venture Exchange (“TSXV“) for the ten (10) trading days ending December 9, 2019. The Agreement remains subject to approval from the TSXV. All Common Shares issued in connection with the Agreement will be subject to a restricted period of four months and one day. There are no finders’ fees payable by the Company in connection with the Agreement.
SOURCE Valens GroWorks Corp.
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Energy Transfer LP, Grubhub, Aurora Cannabis, and The RealReal and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that class action lawsuits have been commenced on behalf of stockholders of Energy Transfer LP (NYSE: ET), Grubhub, Inc. (NYSE: GRUB), Aurora Cannabis, Inc. (NYSE: ACB), and The RealReal, Inc. (NASDAQ: REAL). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Energy Transfer LP (NYSE: ET)
Class Period: February 25, 2017 to November 11, 2019
Lead Plaintiff Deadline: January 20, 2020
On November 12, 2019, the Associated Press reported that Energy Transfer’s Mariner East pipeline project was under investigation by the Federal Bureau of Investigation (“FBI”). Citing interviews with current and former state employees, the Associated Press reported that the FBI’s investigation “involves the permitting of the pipeline, whether [Pennsylvania Governor Tom] Wolf and his administration forced environmental protection staff to approve construction permits and whether Wolf or his administration received anything in return.”
On this news, Energy Transfer’s stock price fell $0.81 per share, or 6.77%, over the following two trading sessions, closing at $11.16 per share on November 13, 2019.
The complaint, filed on November 20, 2019, alleges that throughout the Class Period, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operational and compliance policies. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) Energy Transfer’s permits to conduct the Mariner East pipeline project in Pennsylvania were secured via bribery and/or other improper conduct; (ii) the foregoing misconduct increased the risk that the Company and/or certain of its employees would be subject to government and/or regulatory action; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
SOURCE Bragar Eagel & Squire, P.C.
iX Biopharma secures Australian cannabis manufacture licence
Specialty pharmaceutical company iX Biopharma Ltd (SGX:42C) (“iX Biopharma” or, together with its subsidiaries, “the Group”) is pleased to announce today that its wholly-owned subsidiary, iX Syrinx (“Syrinx”), has been awarded a cannabis manufacture license from the Australian Office of Drug Control under the Narcotics Drugs Act 1967. Under the said licence, the Group is permitted to manufacture and supply extracts and tinctures of cannabis and cannabis resins.
This marks a significant milestone for the Group. Syrinx operates a TGA cGMP certified facility and holds import and export licences for cannabis and State poisons licences; together with the newly granted cannabis manufacture licence, the Group is now able to fully participate in the global medicinal cannabis business.
Importantly, the Group will be able to manufacture and distribute its newly formulated Xativa™ sublingual cannabis wafers in Australia through the Australian Special Access Scheme and in overseas markets. Xativa™ leverages on iX Biopharma’s novel and patented WaferiX™ technology to improve the speed and level of absorption and predictability of effect of medicinal cannabis. Xativa™ provides patients with a more elegant and discreet way to consume medicinal cannabis compared to existing dosage forms for cannabis such as joints, vapes and tinctures, and hence offers a superior user experience. The Group has received feedback from physicians in Australia that the advantages of Xativa™ and its differentiation from the rest of the market offerings are clear and highly desired.
Produced via iX Biopharma’s proprietary freeze-drying technique, the porous and amorphous WaferiX™ matrix holding the active CBD molecules is designed to collapse quickly within the sublingual space. The actives are then transported rapidly across the sublingual membrane into the blood vessels for a rapid onset of action.
“Globally, the use of cannabis for the treatment of a wide range of medical conditions has been growing at an exponential pace. The grant of the cannabis manufacturing licence has come at a most opportune time, allowing us to manufacture, distribute and promote Xativa™ as the gold standard in medicinal cannabis delivery, thereby charting a new growth trajectory for the Group,” said Ms Eva Tan, Director of Corporate and Commercial Strategy of iX Biopharma.
SOURCE iX Biopharma Ltd
Cannabis4 weeks ago
Khiron Launches Kuida Brand in the US, Begins First Sales
Cannabis4 weeks ago
Illinois Scores Best-Selling Cookies Strains in 2020, via Ascend Wellness Holdings
Cannabis3 weeks ago
Cannabis Growth Opportunity Corporation Announces NAV of $2.51
Cannabis4 weeks ago
AMP German Cannabis Group Receives an Import Licence for Medical Cannabis from the German State of Thuringia
Cannabis4 weeks ago
Jushi Holdings Inc. Provides Shareholder Update and Reports Third Quarter 2019 Financial Results
Cannabis2 weeks ago
Is It Safe To Drive On CBD?
Cannabis2 weeks ago
Fire & Flower Receives Two Additional Cannabis Retail Store Licences in Alberta
Cannabis3 weeks ago
Willow Biosciences Reports Third Quarter 2019 Results and Provides Operations Update